Sparks Glencoe, MD, United States of America

Patrick Ha


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2019

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations in Cancer Treatment: The Contributions of Patrick Ha

Introduction

Patrick Ha, an innovative researcher based in Sparks Glencoe, Maryland, has made significant strides in the field of cancer treatment. With one patented invention, he is addressing critical aspects of cancer prognosis and treatment, showcasing the importance of targeted research in healthcare.

Latest Patents

One of Patrick Ha's notable patents is titled "Use of the ZMIZ1 marker in directing treatment and predicting survival in cancer." This invention provides cutting-edge methods and compositions aimed at improving cancer care. The patent outlines a method that involves obtaining a biological sample from a patient and detecting the hypermethylation of the ZMIZ1 gene using specific primers. This detection serves as a crucial factor in directing treatment options and predicting patient survival rates, emphasizing the potential for personalized medicine in oncology.

Career Highlights

Patrick currently works at The Johns Hopkins University, an institution renowned for its contributions to medical research and innovation. His research focuses on the intersection of molecular biology and cancer treatment, where he strives to develop tools that can transform the way cancer is managed. His dedication to improving patient outcomes reflects both his expertise and commitment to the field.

Collaborations

Throughout his career, Patrick has collaborated with esteemed colleagues, including Dimitrios Mathios and Michael Lim. These collaborations likely enhance the research quality and innovation in developing new methodologies for cancer treatment, demonstrating the power of teamwork in scientific advancements.

Conclusion

Patrick Ha's contributions to cancer treatment through his patent reflect a significant step forward in medical innovation. By leveraging the ZMIZ1 marker to direct treatment and predict survival, he is not only advancing the field of oncology but also offering hope for improved patient outcomes. His work at The Johns Hopkins University, alongside his colleagues, continues to inspire future advancements in cancer research and treatment.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…